These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33297893)

  • 1. The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods.
    Deeds SI; Barreto A; Elm J; Derdeyn CP; Berry S; Khatri P; Moy C; Janis S; Broderick J; Grotta J; Adeoye O
    Int J Stroke; 2021 Oct; 16(7):873-880. PubMed ID: 33297893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
    Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
    Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial.
    van der Ende NAM; Roozenbeek B; Smagge LEM; Luijten SPR; Aerden LAM; Kraayeveld P; van den Wijngaard IR; Lycklama À Nijeholt GJ; den Hertog HM; Flach HZ; Wallace AC; Gurewich V; Del Zoppo GJ; Meurer WJ; Lingsma HF; van der Lugt A; Dippel DWJ;
    Trials; 2022 Aug; 23(1):641. PubMed ID: 35945566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Chemical Optimization of Cerebral Embolectomy trial: Study protocol.
    Renú A; Blasco J; Millán M; Martí-Fàbregas J; Cardona P; Oleaga L; Macho J; Molina C; Roquer J; Amaro S; Dávalos A; Zarco F; Laredo C; Tomasello A; Guimaraens L; Barranco R; Castaño C; Vivas E; Ramos A; López-Rueda A; Urra X; Muchada M; Cuadrado-Godía E; Camps-Renom P; Román LS; Ríos J; Leira EC; Jovin T; Torres F; Chamorro Á;
    Int J Stroke; 2021 Jan; 16(1):110-116. PubMed ID: 31852410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.
    Pancioli AM; Adeoye O; Schmit PA; Khoury J; Levine SR; Tomsick TA; Sucharew H; Brooks CE; Crocco TJ; Gutmann L; Hemmen TM; Kasner SE; Kleindorfer D; Knight WA; Martini S; McKinney JS; Meurer WJ; Meyer BC; Schneider A; Scott PA; Starkman S; Warach S; Broderick JP;
    Stroke; 2013 Sep; 44(9):2381-7. PubMed ID: 23887841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
    Bivard A; Garcia-Esperon C; Churilov L; Spratt N; Russell M; Campbell BC; Choi P; Kleinig T; Ma H; Markus H; Molina C; Hsu C; Tsai CH; Meretoja A; Strbian D; Butcher K; Wu T; Davis S; Donnan G; Levi C; Parsons M
    Int J Stroke; 2023 Jul; 18(6):751-756. PubMed ID: 36655938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke.
    Memon MZ; Natarajan SK; Sharma J; Mathews MS; Snyder KV; Siddiqui AH; Hopkins LN; Levy EI
    J Neurosurg; 2011 Apr; 114(4):1008-13. PubMed ID: 20868216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
    Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
    J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.
    Chen HS; Cui Y; Zhou ZH; Dai YJ; Li GH; Peng ZL; Zhang Y; Liu XD; Yuan ZM; Jiang CH; Yang QC; Duan YJ; Ma GB; Zhao LW; Wang RX; Sun YL; Shen L; Wang EQ; Wang LH; Feng YF; Wang FY; Zou RL; Yang HP; Wang K; Wang DL; Wang YL;
    JAMA; 2023 Feb; 329(8):640-650. PubMed ID: 36757755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
    Ciccone A; Valvassori L; Nichelatti M;
    Int J Stroke; 2011 Jun; 6(3):259-65. PubMed ID: 21557814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).
    Barreto AD; Ford GA; Shen L; Pedroza C; Tyson J; Cai C; Rahbar MH; Grotta JC;
    Stroke; 2017 Jun; 48(6):1608-1616. PubMed ID: 28507269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design.
    Albers GW; Campbell BC; Lansberg MG; Broderick J; Butcher K; Froehler MT; Schwamm LH; Nouh AM; Liebeskind DS; Toy F; Yang M; Massaro L; Schoeffler M; Purdon B
    Int J Stroke; 2023 Feb; 18(2):237-241. PubMed ID: 35262424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
    Schellinger PD; Alexandrov AV; Barreto AD; Demchuk AM; Tsivgoulis G; Kohrmann M; Alleman J; Howard V; Howard G; Alexandrov AW; Brandt G; Molina CA;
    Int J Stroke; 2015 Oct; 10(7):1141-8. PubMed ID: 26120902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
    Adeoye O; Sucharew H; Khoury J; Vagal A; Schmit PA; Ewing I; Levine SR; Demel S; Eckerle B; Katz B; Kleindorfer D; Stettler B; Woo D; Khatri P; Broderick JP; Pancioli AM
    Stroke; 2015 Sep; 46(9):2529-33. PubMed ID: 26243231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study).
    Berekashvili K; Soomro J; Shen L; Misra V; Chen PR; Blackburn S; Dannenbaum M; Grotta JC; Barreto AD
    J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3647-3651. PubMed ID: 30249518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design.
    Yang Y; Zhou Z; Pan Y; Chen H; Wang Y;
    Am Heart J; 2020 Jul; 225():38-43. PubMed ID: 32485328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.